# A putative prognostic model for lung adenocarcinoma based on crotonylation-related genes by bioinformatics and experimental verification

**Authors:** Wenting Wang, Baixiang Cui, Haoyue Li, Zihan Zhen, Xueqing Song, Xiaoyu Yuan, Qing Cui, Qi Yuan, Yong Liu

PMC · DOI: 10.3389/fcell.2026.1639773 · Frontiers in Cell and Developmental Biology · 2026-02-17

## TL;DR

This study develops a model to predict lung cancer outcomes using genes related to crotonylation and finds that a gene called FAM83A may help cancer cells grow by boosting glycolysis.

## Contribution

A novel prognostic model for lung adenocarcinoma based on crotonylation-related genes and the identification of FAM83A as a key driver of glycolytic metabolism.

## Key findings

- A crotonylation-related gene model effectively stratifies LUAD patients into high- and low-risk groups with different survival outcomes.
- FAM83A promotes lung cancer cell proliferation by upregulating glycolytic enzymes PKM2 and LDHA.
- High-risk LUAD patients show immune-evasion traits and distinct genomic mutation patterns.

## Abstract

Protein crotonylation is a novel post-translational modification implicated in tumorigenesis and progression. Its putative roles and mechanisms in lung adenocarcinoma (LUAD), however, remain incompletely elucidated.

We analyzed the expression of crotonylation-related genes (CRGs) in LUAD samples and identified differentially expressed genes for gene set variation analysis (GSVA). Using GSVA scores as phenotypic traits, weighted gene co-expression network analysis (WGCNA) was applied to identify key module genes. A putative prognostic model was subsequently constructed via Lasso-Cox regression. Functional enrichment, gene mutation analysis, and immune infiltration analyses were conducted to compare high- and low-risk groups. Furthermore, cellular experiments were performed to validate the putative role of the hub gene FAM83A and its regulation of key glycolytic enzymes PKM2 and LDHA.

We established a putative crotonylation-related prognostic model for LUAD, which effectively stratified patients into high- and low-risk groups with significantly different overall survival. Functional analysis suggested putative disparities in metabolic pathways between the two groups. Mutation landscape analysis revealed distinct genomic variation patterns, while immune infiltration assessment indicated a putative immune-evasion phenotype in high-risk patients. Cellular assays demonstrated that FAM83A enhances lung cancer cell proliferation, putatively through promoting glycolysis. Our findings establish that FAM83A integrates histone H3K27 crotonylation signaling to drive transcriptional reprogramming of glycolytic metabolism, specifically upregulating key enzymes PKM2 and LDHA.

This study proposes a putative prognostic model based on CRGs for LUAD outcome prediction. The hub gene FAM83A may facilitate lung cancer cell growth by regulating glycolysis via PKM2 and LDHA, offering a novel theoretical foundation and a potential target for prognostic assessment and targeted therapy in LUAD patient.

## Linked entities

- **Genes:** SACK1A (scaffolding CK1 anchoring protein A) [NCBI Gene 84985], PKM (pyruvate kinase M1/2) [NCBI Gene 5315], LDHA (lactate dehydrogenase A) [NCBI Gene 3939]
- **Diseases:** lung adenocarcinoma (MONDO:0005061)

## Full-text entities

- **Genes:** RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, PGAM1 (phosphoglycerate mutase 1) [NCBI Gene 5223] {aka HEL-S-35, PGAM-B, PGAMA}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, RS1 (retinoschisin 1) [NCBI Gene 6247] {aka RS, XLRS1}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CD300LG (CD300 molecule like family member g) [NCBI Gene 146894] {aka CLM-9, CLM9, NEPMUCIN, TREM-4, TREM4}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, ENO1 (enolase 1) [NCBI Gene 2023] {aka ENO1-IT1, ENO1L1, HEL-S-17, MPB1, NNE, PPH}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, IGSF10 (immunoglobulin superfamily member 10) [NCBI Gene 285313] {aka CMF608}, SACK1A-AS1 (SACK1A antisense RNA 1) [NCBI Gene 100131726] {aka FAM83A-AS1, HCCC11, HCCC11_v1, HCCC11_v2}, HK2 (hexokinase 2) [NCBI Gene 3099] {aka HKII, HXK2}, CLEC3B (C-type lectin domain family 3 member B) [NCBI Gene 7123] {aka MCDR4, TN, TNA}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, GPI (glucose-6-phosphate isomerase) [NCBI Gene 2821] {aka AMF, CNSHA4, GNPI, NLK, PGI, PHI}, TNNC1 (troponin C1, slow skeletal and cardiac type) [NCBI Gene 7134] {aka CMD1Z, CMH13, TN-C, TNC, TNNC}, GJB2 (gap junction protein beta 2) [NCBI Gene 2706] {aka BAPS, CX26, DFNA3, DFNA3A, DFNB1, DFNB1A}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, KAT7 (lysine acetyltransferase 7) [NCBI Gene 11143] {aka HBO1, HBOA, MYST2, ZC2HC7}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, SACK1A (scaffolding CK1 anchoring protein A) [NCBI Gene 84985] {aka BJ-TSA-9, FAM83A}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, CA4 (carbonic anhydrase 4) [NCBI Gene 762] {aka CAIV, Car4, RP17}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, PGK1 (phosphoglycerate kinase 1) [NCBI Gene 5230] {aka HEL-S-68p, MIG10, PGKA}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ALDOA (aldolase, fructose-bisphosphate A) [NCBI Gene 226] {aka ALDA, GSD12, HEL-S-87p}
- **Diseases:** colorectal cancer (MESH:D015179), N (MESH:C536108), breast cancer (MESH:D001943), CRGs (MESH:C535507), pancreatic cancer (MESH:D010190), HL (MESH:C538324), Cancer (MESH:D009369), Lung cancer (MESH:D008175), tumorigenesis (MESH:D063646), LUAD (MESH:D000077192)
- **Chemicals:** puromycin hydrochloride (MESH:D011691), penicillin (MESH:D010406), 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MESH:C022616), DMEM (-), fatty acid (MESH:D005227), MTT (MESH:C070243), carbon dioxide (MESH:D002245), SYBR Green (MESH:C098022), ATP (MESH:D000255), crotonyl-CoA (MESH:C010701), Glucose (MESH:D005947), formaldehyde (MESH:D005557), PVDF (MESH:C024865), streptomycin (MESH:D013307), lactate (MESH:D019344), retinol (MESH:D014801), glycine (MESH:D005998)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), shFAM83A — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_C6IZ), BEAS-2B — Homo sapiens (Human), Transformed cell line (CVCL_0168), H1299 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0060)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953391/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953391/full.md

## References

44 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953391/full.md

---
Source: https://tomesphere.com/paper/PMC12953391